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Background: Malignant melanoma (MM) is potentially the most dangerous form of skin tumor. In 
the last few years, the so-called TAM receptors, a unique family of tyrosine kinase (TK) receptors, have 
become increasingly important.
Objectives: To evaluate Mer and Axl TAM receptor expression to find clinicopathological features 
that could explain the biological behavior of MM.
Patients and Methods: Clinicopathological data were obtained from an MM electronic database 
at our Institute. We reviewed 24 cutaneous MM specimens. TAM receptor expression was assayed 
using immunohistochemistry. Combinative semiquantitative scoring was used for the evaluation of 
TAM receptor expression (MerTK and AxlTK). Appropriate statistical methods were used to evaluate 
a possible correlation between TAM receptor expression and the clinicopathological variables of the 
MM samples (univariate analysis and multivariate analysis).
Results: MerTK and AxlTK were expressed differently in the MM samples, with a major expression 
of the first receptor. The cells of the tumor microenvironment contributed to the majority of the total 
score. A significant association was found between AxlScore and the site of the tumor and between 
AxlScore and the variable ulceration; another correlation was found between MerScore and the fol-
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ing lymphocytes (TIL), pigmentation, regression, peritumoral 
vascular invasion, nevus-associated MM, and according 
to tumor microenvironment expression. We considered as 
tumor microenvironment the expression of the receptors 
in nonmelanocytic cells in the dermal infiltrate, such as in 
macrophages; this was made possible by using a monoclonal 
antibody against CD163, marker of cells from the monocyte/
macrophage lineage.
TAM receptors were assayed using immunohistochem-
istry. Standard formalin-fixed, paraffin-embedded 4-µm 
sections were stained using rabbit monoclonal immunoglob-
ulin G (IgG) against human MerTK (catalog no. ab52968, 
clone no. Y323, 1:50 dilution; Abcam, UK) and a rabbit 
polyclonal IgG against human AxlTK (catalog no. 8661S, 
clone no. C89E7, 1:600 dilution; Cell Signaling Technology). 
A mouse monoclonal IgG against CD163 (catalog no. 760- 
4437, clone name MRQ-26; Ventana) was used to identify 
histiocytes. Horseradish peroxidase-labeled goat anti-rabbit 
IgG (Zhongshan Golden Bridge Biotechnology, China) was 
used as secondary antibody.
A widely accepted scoring system for immunochemistry 
does not exist yet. In this study we used a combinative semi-
quantitative scoring for both of the TAM receptors analyzed 
(MerTK and AxlTK), which considers the percentage of pos-
itive cells and the intensity of immunohistochemical staining 
in most of the examined fields.
The percentage of positive cells was staged as follows: 0 
(0%-10% of positive cells), 1 (11%-50% of positive cells), 
and 2 (51%-100% of positive cells). This score was calculated 
arbitrarily, taking a cue from the immunoreactivity score 
assessed by other reports [11].
The staining intensity was described using a simple qual-
itative scoring system: “−” score was given for lack of brown 
immunoreactivity, “+/−” score for very weak staining, “+” 
score for weak staining, “++” score for moderate staining, 
and “+++” score for high staining. After that the results were 
converted into grades: “−” score was assigned 0, “+/−” was 
1, “+” was 2, “++” was 3, and “+++” was 4. The 2 scores 
were added together to obtain an intermediate score with 6 
possible values (0 ÷ 6).
The percentage of positive cells and the staining inten-
sity were assessed for each of the following 3 components 
of the tumor: tumoral melanocytes of the dermoepidermal 
Introduction
Malignant melanoma (MM) is potentially the most danger-
ous form of skin tumor, causing 90% of skin cancer mortality 
[1]. Intermittent sun exposure and sunburns are strongly 
related to the development of MM; however, other factors 
may be involved in its pathogenesis [2].
MM has more mutations than any other cancer type, and 
genome aberrations are present in the majority of them. In 
this regard, oncogenic mutations in c-KIT, NRAS, and BRAF 
components of the MAPK pathway have been identified in 
nearly 90% of cutaneous MM [3]; in particular, BRAF and 
NRAS mutations are the most frequently observed [4].
Regarding treatments, highly selective BRAF and MEK 
inhibitors have demonstrated impressive clinical results 
[5]. However, the short duration of response, the acquired 
resistance in most cases, and the toxicity issues support the 
rationale for drug combination approaches to improve the 
outcome of MAPK inhibitors, increasing their efficacy and 
preventing and/or overcoming resistance [6].
In the last few years, the so-called TAM receptors (Mer, 
Axl, and Tyro3), a unique family of tyrosine kinase (TK) 
receptors, have become increasingly important, with a poten-
tial role in the era of targeted therapy [7]. Specifically, Axl 
shows a role in the regulation of invasion and motility of 
tumoral cells; Tyro3 promotes tumor proliferation and acts 
as a positive regulator of MITF in MM, while Mer promotes 
cellular proliferation rather than migration [7-9]. However, 
their specific role in MM is still unknown, given the lack of 
scientific articles addressing the subject. For these reasons we 
aimed to conduct an exploratory evaluation of Mer and Axl 
TAM receptor in primary MM and to find clinicopathological 
features that could be associated with their expression.
Materials and Methods
Clinical and pathological data were obtained from an MM 
electronic database at our Institute, selecting a period of 
research between January 1, 2010, and December 31, 2017.
We reviewed 24 MM specimens, divided by sex (male 
or female), age (≤60 or >60 years), anatomical site (axial 
[head-neck, thorax-thoracic dorsum, abdomen] or peripheral 
[upper and lower limbs]), Breslow thickness (≤0.8 or ≥0.81), 
mitotic rate (<1/mm2 or ≥1/mm2), ulceration, tumor-infiltrat-
lowing characteristics: pathological stage of the tumor (pT), sex, ulceration, and tumor-infiltrating 
lymphocytes.
Conclusions: All correlations between the expression of MerTK and AxlTK with the clinical and 
histological variables of MM should be validated in a large group of people in order to increase the 
validity and the impact of our observations, with subsequently therapeutic implications in the era of 
the “targeted therapy.”
ABSTRACT
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for each clinicopathological variable, stratified according to 
Breslow depth.
Clinical and Pathological Features of the Sample
In the study were enrolled 6 patients with malignant mela-
noma pT1 (pathological stage of tumor 1), 6 patients with 
malignant melanoma pT2, 6 patients with malignant mela-
noma pT3, and 6 patients with malignant melanoma pT4.
Seventeen patients were men and 7 were women. Mean 
age of the patients was 56 years (ranging between 29 and 78 
years). Regarding the anatomical site, 13 patients showed 
involvement of the trunk and 11 had an MM localized to the 
peripheral sites.
A mitotic rate ≥1/mm2 was present in 20 patients, while 
ulceration was present in 11 patients. TIL, assessed only in 
MM with vertical growth, were present in 7 patients and 
absent in 10 samples. Regression phenomenon was observed 
in 7 patients. Four people had an MM with lymphovascular 
invasion, while in 6 cases MM was associated with a preex-
isting nevus (25% of the total).
Correlation of the Expression of Mer and Axl in 
the Analyzed Specimens
Figure 1 shows the trend of MerScore and AxlScore for each 
patient. The expression of Axl was lower than that of Mer. 
The main reason for this finding is that MerTK and AxlTK 
were expressed differently in the MM samples and in the 3 
components of the tumor (tumoral melanocytes of the der-
moepidermal junction, dermal tumoral melanocytes, tumor 
microenvironment [Supplementary Tables e2 and e3]).
The cells of the tumor microenvironment contributed to 
the majority of the total score. The analysis of the CD163 
junction immediately beneath the row of epidermal basal 
cells, dermal tumoral melanocytes, and the cells of the tumor 
microenvironment. Finally, the final score for each patient 
was obtained summing the 3 intermediate scores with 18 
possible values (0 ÷ 18).
In each sample a TAM immunohistochemical reactivity 
of more than 2 was defined as positive.
Data Processing and Statistical Methods
All histopathological and clinical data for each patient in the 
study were collected in an Excel database. Each patient was 
identified with a progressive number to protect his or her 
identity. The variables of interest were summarized according 
to an appropriate statistical description on the basis of their 
type. The score of the expression of the 2 TAM receptors 
(MerTK and AxlTK) was evaluated by 1 observer.
Statistical analysis was conducted using Stata 9.1 software 
(StataCorp, College Station, TX, USA) by another person who 
had no initial knowledge of the detailed clinicopathological 
features of the lesions. A Spearman rank correlation coef-
ficient was used to evaluate the correlation between TAM 
receptors’ staining intensity and the clinicopathological vari-
ables of the MM samples (univariate analysis).
Subsequently, assuming that the effects of the predictive 
variables were constant over time, a multiple logistic regres-
sion was performed (multivariate analysis). In all statistical 
methods, P ≤ 0.05 was considered significant.
Results
A total of 24 patients were included in the analysis. The main 
clinicopathological features of the sample are reported in 
Supplementary Table e1, which shows the number of patients 
Figure 1. Graphical representation of MerScore and AxlScore for each patient.
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4.67 in pT4, showing an atypical distribution with a peak in 
the intermediate stages and lower values in the first and last 
stages (P = 0.04) (Figure 2A). MerScore was 6.82 in men and 
11.57 in women (P = 0.01) (Figure 2B).
The average MerScore was 10.25 in patients ≤60 years old 
and 6.17 in patients >60 years old (P = 0.06), 7.77 in MMs 
of the head-neck, thorax-thoracic dorsum, and abdomen, and 
8.73 in MMs localized on the limbs (P = 0.8).
Regarding histology, we found that the mean values of 
MerScore were 9.22 in superficial spreading melanoma, 5.33 
in nodular melanoma, 6 in acral lentiginous melanoma, and 3 
in lentigo maligna melanoma (P = 0.07) (Figure 2C).
The mean MerScore was 6.6 in patients with a Breslow 
thickness ≤0.80 mm and 8.63 in those with a thickness ≥0.81 
staining revealed that the expression of MerTK was given 
predominantly by these cells.
MerTK was expressed by tumoral melanocytes and the 
cells of the microenvironment; in particular, 13 patients 
expressed MerTK in the dermoepidermal junction’s melano-
cytes (54% of the patients) and 12 in the dermal melanocytes 
(50% of the patients). Only 1 patient did not express MerTK 
in the cells of the tumor microenvironment. In contrast, 
AxlTK was expressed in all patients by the cells of the tumor 
microenvironment; only 1 patient exhibited the expression of 
this TAM receptor also in tumoral melanocytes.
Expression of MerTK
Evaluating MerScore according to pT stage, we found that 
mean MerScore was 6 in pT1, 13 in pT2, 9.17 in pT3, and 
Figure 2. (A) Box plot multiple comparison graph shows the distribution of MerScore (MerS) according to the different stages (pT) of mela-
noma samples. (B) Box plot multiple comparison graph shows the distribution of MerScore according to sex. (C) Box plot comparison graph 
shows the variation of MerScore according to the histology of melanoma: superficial spreading melanoma (SSM), nodular melanoma (NM), 
lentigo maligna (LM), and acral lentiginous melanoma (ALM). (D) Box plot multiple comparison graph shows the distribution of MerScore 
according to the presence or absence of ulceration.
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mm (P = 0.4), 4.75 in MMs with mitoses <1/mm2, and 8.9 in 
those with mitoses ≥1/mm2 (P = 0.1).
The average MerScore was 10 in patients with ulceration 
(P = 0.01) (Figure 2D), 8 in pigmented lesions (P = 0.7), and 
6 in lesions with regression (P = 0.1). Mean Mer expression 
was 9.86 in lesions with TIL and 6.6 in lesions without TIL 
(P = 0.04) (Figure 3).
The mean MerScore was 11.17 in nevus-associated MMs 
(P = 0.1) and 4.67 in cases of microscopic satellites (P = 0.1). 
However, when we performed multiple logistic regression, 
only the variable ulceration maintained statistical significance 
(P = 0.03). All these data are summarized in Table 1.
Subsequently, Kaplan-Meier curves were performed for 
the survival analysis, and the log-rank was used to evaluate 
the difference between the curves (Supplementary Table e4). 
Figure 3. Box plot multiple comparison graph shows the distribu-
tion of MerScore according to tumor-infiltrating lymphocytes (TIL).
MerScore 
(Mean±SD)
Pa Pb
Sex 0.04 NS
 Male 6.82±4.4
 Female 11.57±4.8
Age 0.06 NS
 ≤60 years 10.25±4.6
 >60 years 6.17±4.6
Anatomical site 0.8 NS
  Head-neck/ 
thorax-thoracic 
dorsum/abdomen
7.77±4.5
 Arms/legs 8.73±5.7
Histology 0.07 NS
 SSM 9.22±5.1
 NM 5.33±2.5
 LMM 3
 ALM 6±5.7
pT 0.04 NS
 1 6±4.5
 2 13±3.5
 3 9.17±4.9
 4 4.67±2.8
Breslow depth 0.4 NS
 ≤0.80 mm 6.6±4.8
 >0.81 mm 8.63±5.1
Mitoses 0.1 NS
 <1/mm2 4.75±2.8
 ≥1/mm2 8.9±5.1
MerScore 
(Mean±SD)
Pa Pb
Ulceration 0.01 0.03
 Presence 10±5.5
 Absence 6.69±4.1
TIL 0.04 NS
 Presence 9.86±4.9
 Absence 6.6±4.6
Pigmentation 0.7 NS
 Presence 8±4.6
 Absence 10.5±10.6
Regression 0.1 NS
 Presence 6±4.4
 Absence 9.12±5.0
PVI 0.1 NS
 Presence 4.5±2.1
 Absence 8.95±5.1
Nevus-associated 
melanoma
0.1 NS
 Presence 11.17±5.5
 Absence 7.22±4.5
Microscopic 
satellites
0.1 NS
 Presence 4.67±3.1
 Absence 8.71±5.0
aSpearman test between the variables and MerTK expression.
bMultiple logistic regression between the variables and 
MerTK expression.
Significant values are given in italic.
ALM = acral lentiginous melanoma; LMM = lentigo maligna 
melanoma; NM = nodular melanoma; NS = not significant; 
PVI = peritumoral vascular invasion; SD = standard devia-
tion; SSM = superficial spreading melanoma; TIL = tumor-in-
filtrating lymphocytes.
Table 1. Analysis of Clinicopathological Variables According to MerTK Expression
(data continues next column)
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The mean AxlScore was 4.33 in nevus-associated MMs (P 
= 0.9) and 3.67 in the lesions with microscopic satellites (P 
= 0.3). In the multiple logistic regression only 2 variables 
maintained statistical significance: anatomical site (P = 0.01) 
and ulceration (P = 0.03). All these data are summarized in 
Table 2.
According to the expression of AxlTK in tumoral mela-
nocytes, the patients were divided into 2 groups: AxlTK-neg-
ative (AxlTK−) lesions and AxlTK-positive (AxlTK+) lesions. 
The mean PFS was 76 months in AxlTK− MMs and 94 
months in the positive ones (P = 0.5), while the mean OS was 
79 months in AxlTK− lesions and 94 months in the positive 
ones (P = 0.5). In any case, statistical significance was not 
reached, also due to the low number of AxlTK+ lesions (n = 
1) (Supplementary Table e5).
Subanalysis of Mer and Axl Expression in 
Microenvironment
Evaluating the expression of Mer according to the microen-
vironment, we found that the expression was 4 in median 
Breslow thickness of 2.2 mm (0.24-3.8), 3 in median Breslow 
of 2.3 mm (0.49-4.1), 2 in median Breslow of 2.4 mm (0.2-
4.2), 1 in median Breslow of 2.4 mm (0.9-4.1), and 0 in 
median Breslow of 0.38 mm. The results did not reach statis-
tical significance (Spearman test) owing to the low number 
of patients and the high presence of variables (P = 0.7). Per-
forming the same analysis in Axl we found that, regarding the 
microenvironment, the expression was 4 in median Breslow 
of 0.2 mm (only 1 case), 3 in median Breslow of 1.17 mm 
(0.24-4.2), 2 in median Breslow of 2.7 mm (0.38-7), 1 in 
median Breslow of 4.02 mm (only 1 case). Also in this case 
significance was not reached (P = 0.1).
Discussion
MerTK and AxlTK receptors could play important roles in 
the development of MM: they act as direct drivers of the 
tumor progression and as inhibitory receptors in the cells of 
the tumor microenvironment that suppress host immunity. 
The few published scientific papers that have evaluated the 
expression of MerTK and AxlTK in MM have been mainly 
conducted in vitro on samples of MM cell lines [7,9,11]. 
This study, on the contrary, assessed the expression of these 
tyrosine kinase receptors with immunohistochemical stains 
on biopsy of cutaneous MM specimens.
As previously demonstrated [9], we confirmed the expres-
sion of MerTK and AxlTK in MM samples with a preva-
lence of the first receptor (Figure 5, A-D). Our report also 
demonstrated that these 2 receptors are more expressed by 
the cells of the tumor microenvironment, basically by tumor 
macrophages, as also reported in a recent paper [12]. How-
ever, contrary to Salmi et al [12], who evaluated mainly the 
According to the expression of MerTK in tumoral melano-
cytes, the patients were divided into 2 groups: MerTK-nega-
tive (MerTK−) lesions and MerTK-positive (MerTK+) lesions. 
Mean progression-free survival (PFS) was 55.22 months in 
MerTK− lesions, while it was 93.58 in MerTK+ lesions (P = 
0.004); in the long term, we found that overall survival (OS) 
was 62.9 in MerTK− and 93.76 in MerTK+ lesions (P = 0.02).
Expression of AxlTK
The mean AxlScore was 4.17 in pT1, 6.67 in pT2, 4.5 in pT3, 
and 3.83 in pT4, without reaching statistical significance 
with a P = 0.4. The statistical significance, in the univariate 
analysis, was not reached also for the variable sex (5.06 in 
men and 4.14 in women, P = 0.6). Patients aged ≤60 showed 
a mean AxlScore of 4.42, while in those aged >60 it was 5.17 
(P = 0.5). The lesions localized on the head-neck, thorax-tho-
racic dorsum, or abdomen, in contrast to those localized to 
the limbs (arms, legs), showed a mean AxlScore of 5.62 and 
3.82, respectively (P = 0.01) (Figure 4).
Regarding histology, we found that mean AxlScore val-
ues were 5.11 in superficial spreading melanoma, 4.33 in 
nodular melanoma, 3 in acral lentiginous melanoma, and 
3.5 in lentigo maligna (P = 0.2). The average AxlScore was 
4.4 in patients with Breslow thickness ≤0.80 mm and 4.89 in 
patients with a thickness ≥0.81 mm (P = 0.4), 4.75 in MMs 
with mitoses <1/mm2, and 4.8 in those with mitoses ≥1/mm2 
(P = 0.3). The average AxlScore was 4.27 in patients with 
ulceration (P = 0.9), 4.86 in pigmented lesions (P = 0.4), 
4.14 in lesions with regression (P = 0.7), 6.75 in lesions with 
peritumoral vascular invasion (P = 0.5), and 3.83 in patients 
without perineural invasion. Mean Axl expression was 6.29 
in lesions with TIL and 4.1 in lesions without TIL (P = 0.8). 
Figure 4. Box plot multiple comparison graph shows the distribu-
tion of AxlScore according to the anatomical site (axial: head-neck, 
trunk; extremities: upper and lower limbs).
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(P = 0.04). It is possible to assume a plausible role of the 
estrogen receptor in determining this difference between the 
sexes, since data have increasingly demonstrated a role of this 
receptor in the biology of MM [13,14]. Moreover, it has been 
demonstrated that breast cancer, a hormone-sensitive tumor, 
expresses a high level of TAM receptor [15].
The ulceration of the primary tumor also correlates with 
a more elevated expression of MerTK (P = 0.01). More than 
half of the ulcerated MMs (6/11) are pT2 and pT3 tumors, 
which are the stages with discrete proliferation rates and 
invasiveness. MerTK induces upregulation of focal adhesion 
kinases, which promotes migration [16]. Moreover, it has 
been found that MerScore was higher in patients with the 
presence of TIL (P = 0.04).
expression of TAM receptors in CD68+ and CD163+ mac-
rophages in benign and malignant melanocytic lesions, our 
study focused on the correlation between the expression of 
TAM receptors and the histological main types of MM, with 
the relative clinicopathological correlations.
We found a significant expression of MerTK in pT2 and 
pT3 MM, with low levels in initial and advanced tumors; 
MerTK surely has an important implication in the biological 
regulation of these 2 stages, and probably this is associated 
with different biological pathways between the initial tumor-
igenesis and more advanced primary tumors.
The univariate correlation has also evidenced a significant 
association between MerTK expression and sex: women 
have a more elevated expression of this receptor than men 
AxlScore 
(Mean±SD)
Pa Pb
Sex 0.6 NS
 Male 5.06±3.2
 Female 4.14±1.1
Age 0.5 NS
 ≤60 years 4.42±1.2
 >60 years 5.17±3.8
Anatomical site 0.01 0.01
  Head-neck/ 
thorax-thoracic 
dorsum/abdomen 
5.62±3.5
 Arms/legs 3.82±1.1
Histology 0.2 NS
 SSM 5.11±3.1
 NM 4.33±0.6
 LMM 3
 ALM 3.5±2.1
pT 0.4 NS
 1 4.17±2.9
 2 6.67±4.2
 3 4.50±3.1
 4 3.83±2.1
Breslow depth 0.4 NS
 ≤0.80 mm 4.4±1.3
 >0.81 mm 4.89±3.0
Mitoses 0.3 NS
 <1/mm2 4.75±1.3
 ≥1/mm2 4.8±3.0
AxlScore 
(Mean±SD)
Pa Pb
Ulceration 0.9 0.03
 Presence 4.27±1.00
 Absence 5.23±3.6
TIL 0.8 NS
 Presence 6.29±4.7
 Absence 4.1±1.0
Pigmentation 0.4 NS
 Presence 4.86±2.9
 Absence 4±0
Regression 0.7 NS
 Presence 4.14±1.2
 Absence 5.06±3.2
PVI 0.5 NS
 Presence 6.75±6.9
 Absence 4.4±0.9
Nevus-associated 
melanoma
0.9 NS
 Presence 4.33±0.8
 Absence 4.94±3.2
Microscopic 
satellites
0.3 NS
   Presence 3.67±1.5
   Absence 4.95±2.9
aSpearman test between the variables and AxlTK expression.
bMultiple logistic regression between the variables and AxlTK 
expression.
Significant values are given in italic.
ALM = acral lentiginous melanoma; LMM = lentigo maligna 
melanoma; NM = nodular melanoma; NS = not significant; 
PVI = peritumoral vascular invasion; SD = standard devia-
tion; SSM = superficial spreading melanoma; TIL = tumor-in-
filtrating lymphocytes.
Table 2. Analysis of Clinicopathological Variables According to AxlTK Expression
(data continues next column)
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The main limitation of our study is the small size of the 
sample. All the correlations between the expression of MerTK 
and AxlTK with the clinical and histological variables of 
MM should be validated in a large group of people in order 
to increase the validity and the impact of the observations. 
Therefore, a multivariate analysis and a proper sample size 
could demonstrate the actual role of these TK receptors. 
However, at the same time, the present findings could also 
be a consequence of the bias if the receptors show a different 
pattern of expression according to stage and other prognostic 
factors.
Another limitation of this study is that the cross-sec-
tional analysis between the TAM receptor scores (AxlScore 
and MerScore) and the clinicopathological variables of the 
tumor was done only at the time of its diagnosis. Our anal-
ysis established a simple association between these scores 
and the different variables. An analysis of the expression of 
these receptors could also be evaluated during the patient’s 
follow-up, according to the tumor progression in order to 
hypothesize a pathogenetic correlation.
The statistical analysis found an association between 
MerScore of tumoral melanocytes and PFS/OS (P = 0.004 and 
0.02, respectively): the patients whose MerTK expression in 
tumoral melanocytes is higher have a better prognosis; this 
evidence can be explained by the fact that the presence of TIL 
correlates with a favorable course [17]. This finding may have 
predictive clinical implications and could have a role in the 
organization of the follow-up of the patient with MM; for 
example, medical examinations could be closer in patients 
with a low tumoral melanocyte expression of MerTK.
The univariate statistical analysis regarding the expres-
sion of AxlTK revealed a significant association between the 
AxlScore and the anatomical site of the tumor (P = 0.01); in 
particular, those MMs that are localized to head-neck, tho-
rax-thoracic dorsum, and abdomen have a higher AxlScore 
than those on arms and legs. This reflects a different impor-
tance of this receptor in the MM pathogenesis according to 
the anatomical sites. It is well known that various genetic 
alterations differ with the anatomical site of MM, and prob-
ably this happens also for AxlTK expression [18].
Figure 5. (A) Cutaneous melanoma, pT3 (H&E, ×40). (B) CD163, in the same melanoma as depicted in panel A (×40). (C) MerTK, in the 
melanoma depicted in panel A (×40). (D) AxlTK, in the melanoma depicted in panel A (×40).
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Conclusions
This is a preliminary and exploratory study that correlates 
the clinicopathological characteristics of primary cutaneous 
MM with the levels of the immunohistochemical expression 
of MerTK and AxlTK. Moreover, it is a first attempt to eval-
uate a possible association between the expression of these 2 
receptors and the prognosis of the patients. This study could 
be expanded with the evaluation of the expression of the 
TAM receptor in metastatic melanomas and the screening 
of the mutation of the oncogenes nRAS, BRAF, and c-KIT 
with subsequently therapeutic implications in the era of the 
“targeted therapy.”
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Supplementary Table e1. Clinicopathological Baselines of the Sample
pT1 pT2 pT3 pT4
Sex
 Male 3 3 5 6
 Female 3 3 1 0
Age
 ≤60 years 3 4 2 3
 >60 years 3 2 4 3
Anatomical site
 Head-neck 0 0 1 1
 Thorax-thoracic dorsum 2 3 1 2
 Abdomen 0 2 1 0
 Arms 2 0 0 2
 Legs 2 1 3 1
Histology
 SSM 5 6 5 2
 NM 0 0 1 2
 LMM 1 0 0 0
 ALM 0 0 0 2
Breslow depth (mean± SD, mm) 0.47±0.26 1.50±0.28 2.95±0.63 4.59±1.18
Mitoses
 <1/mm2 4 0 0 0
 ≥1/mm2 2 6 6 6
Ulceration
 Presence 1 3 3 4
 Absence 5 3 3 2
TIL
 Presence 0 3 2 2
 Absence 1 1 4 4
Pigmentation
 Presence 6 6 5 5
 Absence 0 0 1 1
Regression
 Presence 3 1 0 3
 Absence 3 5 6 3
PVI 
 Presence 0 1 1 2
 Absence 6 5 5 4
PNI
 Presence 0 0 0 0
 Absence 6 6 6 6
Nevus-associated melanoma
 Presence 0 4 0 2
 Absence 6 2 6 4
Microscopic satellites
 Presence 0 0 1 2
 Absence 6 6 5 4
ALM = acral lentiginous melanoma; LMM = lentigo maligna melanoma; NM = nodular melanoma; 
PNI = perineural invasion; pT = pathological stage of tumor; PVI = peritumoral vascular invasion; SD = 
standard deviation; SSM = superficial spreading melanoma; TIL = tumor-infiltrating lymphocytes.
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Supplementary Table e2. Expression of MerTK 
According to 3 Different Components of the Tumor
pT1 pT2 pT3 pT4
MerTK
  Dermoepidermal junction’s 
tumoral melanocytes
30.56% 30.77% 21.82% 10.71%
  Dermal tumoral melanocytes 13.89% 30.77% 23.64% 10.71%
  Tumor microenvironment 55.55% 38.46% 54.54% 78.58%
Supplementary Table e3. Expression of AxlTK 
According to 3 Different Components of the Tumor
pT1 pT2 pT3 pT4
AxlTK
  Dermoepidermal junction’s 
melanocytes
0% 15% 0% 0%
 Dermal melanocytes 0% 15% 0% 0%
  Tumor microenvironment 25% 70% 100% 100%
Supplementary Table e5. Survival Analysis 
According to Axl Expression
PFS 
(Months±SD)
Pa
OS 
(Months±SD)
Pa
Axl− 76±31.2 0.5 79±29.6 0.5
Axl+ 94 94
aKaplan-Meier product and log-rank test.
OS = overall survival; PFS = progression-free survival; SD = standard deviation.
Supplementary Table e4. Survival Analysis 
According to Mer Expression
PFS 
(Months±SD)
Pa
OS 
(Months±SD)
Pa
Mer− 55.22±36.3
0.004
62.9±35.4
0.02
Mer+ 93.58±13.6 93.76±11.6
aKaplan-Meier product and log-rank test.
Significant values are given in italic.
OS = overall survival; PFS = progression-free survival; SD = standard deviation.
